Shares of uniQure plummeted more than 40% in premarket trading Monday after the company confirmed the FDA has rejected its ...
A senior FDC official said the product is a “failed therapy” and confirmed that regulators have asked uniQure to run a new ...
Analysts say second fatality heightens safety concerns, raises doubts about future demand Both patients suffered from acute liver failure Sarepta suspends forecast, stops shipments of therapy to some ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results